articleThe LancetSep 19, 2019Closed access

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Ghent University · Karolinska Institutet · +21 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,451
total citations
FWCI
100.69
Percentile
100%
References
32
Citations per year

Authors

34

Topics & keywords

Keywords
  • Medicine
  • Dupilumab
  • Nasal polyps
  • Placebo
  • Internal medicine
  • Placebo-controlled study
  • Sinusitis
  • Clinical endpoint
UN Sustainable Development Goals
  • No poverty
No related works found for this paper.